Traci Wicks’ Post

As most of you know, sadly my husband's cancer battle ended 3 months ago. Kyle battled stage 4 pancreatic cancer for 17 long hard months. Kyle was a General Partner at Edward Jones and was with the firm for 25 years. Starting his career in a small office in Dillon, MT as a Financial Advisor, he worked his way up to a General Partner role which is the reason we now reside in St Louis, MO. So why am I sharing all this with you? I am sharing this in hopes you will help me on our quest to continue his legacy in another way. After 5 months of standard treatment, his Oncologist and I were able to work together to get a novel treatment into his body that never before had been administered in a human's body. His Oncologist, Dr. Kian Lim had been working on this treatment for years. Lucky for us, Kyle was the first patient to receive this treatment and it worked! The reality is GI cancers are on the rise... Why, you ask? Likely because of lifestyle choices and environmental challenges beyond our control according to the experts. We have started The Kyle Andersen Fund to help get a phase 1 study off the ground quickly for Dr. Lim and his team. Initially we thought we would have to raise $3M in order for Kyle to get the medication, however,  fortunately he was granted Compassionate use of this novel treatment in March of 2022 and by December his cancer was non-active!!!! We were elated and ready to start this new chapter unfortunately Kyle ended up passing away due to complications beyond our control. April 3, 2023 after his courageous fight with one of the worst diseases known to man, he took his last breath. Cancer is taking too many lives, and too many too soon. He was expertly treated at Siteman and was the recipient of cutting edge treatment that held promise and gave hope. I have committed to raising money for the researchers at Siteman, like those who made Kyle’s pancreas treatment possible, so that young families like mine never loose their spouse/soulmate/father too soon, too young.  Siteman is an overall Top 10 comprehensive cancer center nationally, and a Top 5 for clinical trials. Pancreatic research and trials are a particular strength at Siteman.  Please support my effort and Kyle’s legacy as we continue to fund Siteman’s cutting-edge research for pancreatic and all other cancers. Together we will raise the standard of care for everyone, leading to far fewer deaths, and ultimately a world without cancer….. Please see links below to DONATE or join TEAM KYLE and fundraise with me!! To DONATE: https://lnkd.in/gE34bUEH To RIDE: https://lnkd.in/gPCzTcxu

Q the DISCLOSURE, [Dec 20, 2023 at 10:23 AM] What sunscreen looks like when exposed to ultraviolet light. Even if you wash your face, sunscreen stays on your skin and increases your chances of getting cancer. Join👇 https://lnkd.in/e4Fry99k

Congrats to the solid tumor TM team members for getting this paper out! Team conducted comprehensive immunophenotyping using mass & flow cytometry of tumor-infiltrating lymphocytes (TILs) & peripheral blood mononuclear cells (PBMCs) from two independent cohorts of samples from patients with various solid tumor types to identify human immune cell subsets that express LAG-3 and it’s ligands. They also investigated the potential relationship between LAG-3 expressing subsets and clinical outcomes to IO-therapies by profiling peripheral immune cells using scRNA-seq on samples from a clinical trial cohort of melanoma patients treated w/ immunotherapy. Congrats to all on this collaborative team effort! #LAG3 #immunooncology #translationalresearch

Thinking of adopting a child of another race? Wondering about adoption after battling cancer? Take a listen!! This is a GREAT conversation! #theadoptionroadmappodcast

#ICYMI: OncoDaily recently featured #IOLC2024! 🎉The #OncoDaily mission is to empower patients, survivors, and professionals with the #knowledge and #inspiration they need to fight cancer. ➡️ https://bit.ly/3UOpyRZ Follow their page to stay informed, inspired, and connected! And if you haven't already, click here 📲 https://bit.ly/3u3BDnp to secure your space for the 8th Annual IOLC at the #earlybird rates. Act fast, space is limited! ⌛ 🗓️ 10-12 November, 2024 📸 Photo credits: Hôtel du Louvre via gallery . #oncology #leadership #conference #ParisConference #EUCancerPlan #Policy #Research #Cancer #Advocacy #continuingeducation #globalhealthcare #collaboration #mandriergroup #mandriermeetings #knowledgesharing #internationalconference #OncologyLeadership #EuropeanHealthCare #innovation #insights #bestpractices #ClinicalLeadership Association of Cancer Executives

Victorian Cancer Plan 2024-2028: have your say The Victorian Government has published a consultation paper to guide discussion and feedback from the cancer control sector, health services, prevention and population health sectors, researchers and consumers to inform how the Victorian Government will improve cancer outcomes for all Victorians. Through consultation the Victorian Government aims to understand:  • what is important to people affected by cancer  • how the system can best plan for and respond to their diverse and changing needs  • how we can continue to reduce access barriers and inequitable outcomes  • what steps we need to take to continue to build a world-class, sustainable cancer system in Victoria. https://lnkd.in/gcgNG8z4

Check out this blog post in Nature Research Communications, written by Isabelle (Qiyuan) Hu, summarizing our team's work on developing an MSI predictor from histopathology images of prostate cancer! 👏

Have you already seen our Key Takeaways from SCOPE? #scope #scope2024 #citeline #clinicaltrials

🌟 The Power of Collaboration: UNICA4EU Team Leading the Way! 🤝✨ At #UNICA4EU, we firmly believe that teamwork and collaboration are the keys to making a lasting impact in the fight against #childhoodcancer. Our team comprises a remarkable blend of dedicated professionals from various fields, all working together towards a common goal. 🏥 5 leading medical and research institutions specializing in pediatric oncology. Their expertise and dedication form the backbone of our mission, ensuring that we stay at the forefront of cutting-edge treatments and care pathways for children battling cancer. 🌍 🤖💡 3 exceptional experts in Artificial Intelligence (AI), Machine Learning (ML), bioinformatics, and computational biology. They play a pivotal role in harnessing the power of technology to revolutionize the way we combat Childhood Cancer, exploring innovative AI applications to improve diagnosis, treatment, and survivorship. 🔬 🌈 5 reference networks for Childhood Cancer in Europe. These networks provide invaluable support, collaboration, and guidance, strengthening our collective efforts to enhance care pathways and ensure that children have access to the best possible treatments and support systems. 🤝 🤝 2 experts in community building and impact creation. They are instrumental in fostering collaboration, engaging patient advocates, parents, and survivors, and ensuring that the voices of those affected by Childhood Cancer are heard and incorporated into our initiatives. Together, we create a supportive and empowering community that drives positive change. 👨👩👧👦 https://unica4.eu/team/ SIOP Europe, the European Society for Paediatric Oncology (SIOPE) AUSTRALO Childhood Cancer International - Europe Ospedale Pediatrico Bambino Gesù Humanitas Universität des Saarlandes St. Anna Children's Cancer Research Institute (CCRI) International Foundation for Integrated Care (IFIC) Innovative Therapies for Children with Cancer PanCare Università degli Studi di Milano-Bicocca Prinses Máxima Centrum voor kinderoncologie Università degli Studi di Padova Sant Joan de Déu Universidad Politécnica de Madrid #UNICA4EU #horizoneurope #EUCancerlPlan

Amazing to have witnessed the ~15 year bench-to-bedside odyssey of vamorolone, great work everyone ! To summarize, vamorolone is a structurally unique steroidal anti-inflammatory drug (a glucocorticoid like prednisone) to treat children and adolescents living with Duchenne muscular dystrophy (DMD). This multi-functional drug shows potent inhibition of pro-inflammatory NFkB pathways via high-affinity binding to the glucocorticoid receptor, high-affinity antagonism for the mineralocorticoid receptor, and membrane stabilization properties. This novel therapy (the first new glucocorticoid drug in decades) demonstrates similar efficacy to traditional corticosteroids with reduced negative downstream impacts or side effects, as such it will eventually have applications well beyond the treatment of DMD.